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Background. Helicobacter pylori (HP) infection is the most common infection in the world and coronary artery disease (CAD) is
probably associated with it. The aim of this prospective study was to evaluate the association between HP infection and CAD in
suspected patients referred for coronary angiography.The coronary angiographywas performed using Judkinsmethod and patients
were assigned to participate in CAD positive (>50% luminal diameter stenosis) and negative groups. The serum HP IgG antibody
was checked. Results. Positive and negative CAD groups consisted of 62 and 58 patients, respectively. HPwasmore prevalent among
CAD+ patients, and with increasing the number of coronary arteries with stenosis, the HP seropositivity increased so that 76.3% of
patients withmultiple vessel diseases (MVD) and 70%of patients with single vessel diseases (SVD)wereHP seropositive versus 50%
in control group (𝑃 = 0.006). Positive CADwas significantly associated with HDL level (𝑃 = 0.01) and ESR level (𝑃 = 0.006). Also,
CAD+ patients had higher CRP levels than controls and it was statistically different between SVD group and controls (𝑃 < 0.05).
Conclusion.HP infection is more prevalent in CAD positive patients and, in case of proving causal relationship, it can be considered
as a reversible risk factor for CAD.
1. Introduction
Nowadays the most common risk factors for atherosclerosis
process which cause coronary heart diseases (CHD) include
diabetes, dyslipidemia, hypertension, and smoking [1]. The
inflammation processes and atherogenesis have many simi-
larities, and the role of an active inflammatory process in ath-
erosclerosis pathogenesis of the coronary circulation is grow-
ing. Significantly, monocytes and macrophages are recog-
nized as components of atheromatous plaques for several
years. The risk of cardiovascular events is associated with
increased levels of the acute phase proteins, fibrinogen, C-
reactive protein (CRP), and proinflammatory cytokines [2].
For this reason, chronic inflammation is considered as a
risk factor for CHD, and vascular injury, inflammation, and
thrombosis are considered to cause atherosclerosis whereas
the stimulus that generates the inflammatory response has
remained unclear [3, 4].
Helicobacter pylori (HP) infection is the most common
infection round the world, particularly in the developing
countries, and is an etiological factor for the development of
peptic ulcer and gastric cancer [5]. HP infection is reported to
be associated withmany extra gastrointestinal manifestations
such as hematological diseases like idiopathic thrombo-
cytopenic purpura (ITP) and unexplained iron deficiency
anemia; neurological disorders like stroke and Parkinson and
Alzheimer’s disease; obesity and skin disorders. Among these,
ITP and unexplained iron deficiency anemia have the best
evidence and high quality studies show the improvement of
iron deficiency anemia and ITP after HP eradication [6–8].
Many reports suggest that chronic infections may be
associated with atherosclerosis and vascular disease. Placing
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the inflammation as a cardiovascular risk factor in one hand
and HP involvement in extra digestive disorders on the other
hand made researches evaluate the HP role in atherosclerosis
processes [9].The evidence of its association with CAD is
weak and many of the results may be erroneous [6–8].
During the last years, many studies have been performed
on the relationship between HP infection and atherosclerotic
diseases such as stroke and ischemic heart disease [10]. Some
studies have found the role of CagA positive strain of this
pathogen in CHD [11, 12]. Khodaii et al. confirmed that the
patients with AMI had a significantly higher prevalence of
HP infection and CagA seropositivity than the control popu-
lation [13].
On the contrary, some studies did not show any associ-
ation between HP and CAD [14, 15]. It is assumed that an
undetected chronic infection may be behind these changes
in inflammatory markers and highlights microorganisms
that are commonly detectable in asymptomatic individuals.
Hence, the aim of this study was to evaluate the association
between HP infection and coronary artery disease.
2. Materials and Methods
2.1. Patients. In this cross-sectional study, 120 patients with
suspected CAD referred to Shahid Beheshti Hospital of Qom
(Iran) for coronary angiography were prospectively enrolled
from January to June 2013 and all of them underwent physical
examinations. In data evaluation, age, gender, body mass
index (BMI), patient’s history (history of hypertension (indi-
cated by systolic blood pressure ≥140mmHg, diastolic blood
pressure of ≥90mmHg, or antihypertensive medication),
diabetes mellitus, stroke, CCU admission, cardiac diseases
and cardiac failure, renal insufficiency, and smoking (Patients
who had stopped smoking for 10 years or less were classified
as smokers)), and biochemical parameters (hemoglobin, leu-
cocytes, thrombocytes, total cholesterol, low density lipopro-
tein (LDL) cholesterol, high density lipoprotein (HDL)
cholesterol, triglycerides, creatinine, glycemia, CRP, andESR)
were recorded.
Patients with severe renal (creatinine >2mg/dL) or hep-
atic failure, anemia, endocrine or neurological diseases or
malignancies, and previous HP infection treatment were
excluded.
After 8 hours of fasting overnight, venous blood samples
were obtained and stored at 4∘C. Serum was acquired by
centrifugation of blood samples at 2000 r/min for 15 minutes,
immediately after sampling. The serum HP IgG antibody
was measured using ELISA kit, Padtan Elm Co., Iran, and
seropositivity HP was detected based on the serum titers of
higher than 30AU/mL.
2.2. Coronary Angiography. Coronary angiography was per-
formed by femoral artery using Judkins method [16]. Two
experienced cardiologists unaware of the patients’ enrollment
reviewed all angiograms. If they did not have the same view,
the third cardiologist saw the angiographic film and then,
based on angiographic results, patients were divided into two
groups with and without coronary artery disease.
Coronary artery disease was defined as more than 50%
luminal diameter stenosis of at least one coronary artery and
patients with CAD were divided into groups of single- or
multi vessel disease. Patients without CAD were divided into
subgroups of insignificant atherosclerosis (luminal diameter
narrowing <50%) or normal (without luminal diameter
narrowing).
2.3. Statistical Analysis. Basic statistical description of the
study population adopted percentage proportions for cat-
egorical parameters while the continuous variables were
expressed as mean and 95% confidence interval (CI). Sig-
nificant differences among groups were tested with one-way
ANOVA and Bonferroni post hoc test for continuous vari-
ables and 𝜆2 test for categorical variables. Bonferonni post-
hoc test was adopted as a solution for multiple testing prob-
lems; it is the correction for increased level of type I error
during multiple testing with objective to reach 0.05 for all
tests. Predictors in logistic regression were described by their
odds ratio and CI; their statistical significance was tested
using Wald test which is a standard test for testing whether
an independent variable has a statistically significant rela-
tionship with a dependent variable. Hosmer and Lemeshow
test was used for statistical significance of the whole logistic
models, analyses were performed using SPSS 16.0, and a
𝑃 value less than 0.05 was considered as being statistically
significant.
2.4. Ethics. All individuals signed informed consent prior to
their enrolment in the study. Also, the study was planned
according to the ethical guidelines following the Declaration
of Helsinki and Ethics Committee of Qom University of
Medical Sciences approved it.
3. Results
In this study 120 patientswere allocated in two groups accord-
ing to positive (62 patients) and negative CAD (58 patients).
Detailed division in subgroups with single- and multi vessel
CAD (positive CAD) and insignificant atherosclerosis group
and control group (negative CAD) is presented in Tables 1-2.
The differences in basic characteristics and risk factors
are presented in Table 1. It had significant differences between
patients with MVD and controls by age and BMI (𝑃 < 0.05).
Otherwise, in male gender, a significant difference was found
between patients with MVD and patients with insignificant
atherosclerosis (𝑃 < 0.05). Although patients with CAD
had higher rates of hypertension and diabetes, it was not
statistically significant (Table 1).
The basic differences in laboratory parameters are pre-
sented in Table 2. Helicobacter pylori infection had a higher
prevalence in patients with coronary artery disease and the
greater the number of coronary artery stenosis is, the higher
the rate ofHP infectionwas observed so that 76.3%of patients
with MVD and 70% of patients with SVD had HP infection
while it was 50% in normal patients and this difference was
statistically significant (𝑃 < 0.05) (Table 2).
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Age† 56.2 (54.14–58.26) 59.4 (55.7–63.1)∗ 56.4 (52.3–60.5) 56.3 (52.5–59.9) 49.9 (43.7–56.1)
Male gender† 50.8 66.7# 46.2 39.5 50
Height (cm) 162.1 (160.4–163.8) 164.1 (161.1–167.1) 162.1 (157.5–166.7) 160.1 (157.4–162.8) 162.2 (158.1–166.3)
Weight (kg) 75.4 (72.8–78) 74 (69.5–78.5) 73 (67.1–78.9) 74.3 (69.8–78.8) 82.7 (74.6–90.8)
BMI (kg/m2)† 28.7 (27.8–29.6) 27.5 (25.9–29.1)∗ 27.7 (25.8–29.6) 29 (27.3–30.7) 31.6 (28.6–34.6)
Risk factors (%)
Hypertension 60 61.1 73.1 57.9 45
Diabetes mellitus 29.2 36.1 26.9 26.3 25
History of cardiac disease†§ 30.8 38.9# 42.3# 15.8 30
History of CCU admission††§ 45.8 55.6## 61.5## 23.7∗∗ 50
History of cardiac failure 50.8 50 61.5 42.1 55
Smoking experience 17.5 27.8 11.5 13.2 15
Categorical variables are presented in %, continuous variables as mean (95% confidence interval).
†Significant difference among groups: ANOVA/Chi-square test (𝑃 < 0.05), ††significant difference among groups: ANOVA/Chi-square test (𝑃 < 0.001),
∗significant difference versus control group: Bonferroni test (𝑃 < 0.05), ∗∗significant difference versus control group: Chi-square test (𝑃 < 0.001), §significant
difference betweenCADpos. andCADneg.: Chi-square test (𝑃 < 0.050), #significant difference versus insignificant atherosclerosis: Chi-square test (𝑃 < 0.05),
##significant difference versus insignificant atherosclerosis: Chi-square test (𝑃 < 0.001); BMI: body mass index.
Table 2: Laboratory markers in groups of CAD.
All patients
(𝑁 = 120)











HP Seropositive (%)†§ 62.5 76.3#¥ 70# 52.8 50
CRP† 6.25 (4.55–7.95) 6.2 (2–10.2) 8.4∗ (3.8–13.1) 5.2 (3.7–6.7) 5.5 (2.4–8.6)
ESR†§ 13.7 (11.1–16.3) 17.2∗ (10.8–23.5) 17∗ (10.7–23.3) 10.3 (7.1–13.5) 9.5 (5.2–13.8)
Total Chol 145 (138–152) 155.5 (142.5–168.5) 136.5 (122.3–150.7) 144.2 (132.6–155.8) 138.8 (120–157.8)
HDL†† 48.5 (46.6–50.4) 49.5 (45.9–52.9) 43.8 (39.1–48.5)## 53.6 (50.5–56.7)∗∗ 43.2 (39.9–46.5)
TG 149.7 (133.3–166.1) 154.6 (123–186.2) 150.7 (120.9–180.3) 140.9 (111.3–170.5) 156 (104.5–208.1)
LDL 69.6 (63.1–76.1) 79.3 (66.1–92.5) 61.8 (49.7–73.9) 68.6 (55.2–82) 64 (52–76)
Creatinine† 1.08 (0.95–1.2) 1.06 (0.99–1.2) 0.94 (0.89–1)∗ 0.95 (0.9–1)∗ 1.5 (0.76–2.2)
Categorical variables are presented in %, continuous variables as mean (95% confidence interval), and due to not normal distribution logarithmic
transformation of the data was needed. †significant difference among groups: ANOVA/Chi-square test (𝑃 < 0.050), ††significant difference among groups:
ANOVA/Chi-square test (𝑃 < 0.001), §significant difference between CAD pos. and CAD neg.: Chi-square test (𝑃 < 0.050), #significant difference versus
insignificant atherosclerosis: Chi-square test (𝑃 < 0.050), ##significant difference versus insignificant atherosclerosis: Bonferroni test (𝑃 < 0.001), ∗significant
difference versus control group: Bonferroni test (𝑃 < 0.05), ∗∗significant difference versus control group: Bonferroni test (𝑃 < 0.001), and ¥significant
difference versus control group: Chi-square test (𝑃 < 0.050).
Patients with CAD had higher CRP levels compared
to normal patients and this difference was statistically sig-
nificant between SVD patients in comparison with control
group (𝑃 < 0.05) (Table 2). Also, creatinine level was signif-
icantly decreased in both SVD and insignificant atheroscle-
rosis group against controls (𝑃 < 0.05). HDL cholesterol
was significantly lower in SVD group against insignificant
atherosclerosis group and also it was significantly higher in
insignificant atherosclerosis group against controls.
The linear logistic regression showed association of
patient’s biochemical markers, basic characteristics, and risk
factors on presence of CAD (Table 3). From biochemical
markers, positive CAD was significantly associated with HP
infection (OR = 3.86, 95% CI = 1.48–10; 𝑃 = 0.006) and HDL
(OR = 0.92, 95%; CI = 0.86–0.96; 𝑃 = 0.01) and ESR level
(OR = 1.07, 95%, CI = 1.02–1.13; 𝑃 = 0.006) (Table 3). On the
other hand, presence of positive CADwas influenced only by
HP infection and HDL and ESR level. From clinical factors,
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Table 3: Influence of patient’s basic characteristics and biochemical parameters on presence of disease based on linear logistic regression.
Variable OR 95% confidence interval 𝑃 value
Age 1.04 1.00–1.08 0.049
Male gender 3.03 1.02–8.95 0.045
HDL 0.92 0.86–0.98 0.01
ESR 1.07 1.02–1.13 0.006
HP seropositive 3.86 1.48–10 0.006
significant relationship was found between age, male gender,
and positive CAD (SVD and MVD as well).
4. Discussion
It seems that CHD is one of the extra gastrointestinal diseases
and some studies showed its association with HP infection
[15, 17]. The role of inflammation mechanism in the patho-
genesis and progression of coronary artery disease has been
increasingly explored but still remains to be elucidated.
Epidemiological studies based on serological findings have
suggested an association between chronic HP infection and
atherosclerosis, although controversies exist. In Izadi et al.’s
study on 105 patients under CABG, PCR test result was posi-
tiveHelicobacter species for 31 (29.5%) specimens from coro-
nary artery atherosclerotic plaques. Also in serologic tests 25
(23.8%)were positive forHP immunoglobulinA (IgA) and 56
(53.3%) were positive for anti-HP immunoglobulin G (IgG)
[18]. This study and other studies suggest this hypothesis that
HP can be associated with CAD or even consider it as a risk
factor that plays a role in atherosclerosis plaque formation
[9, 19]. HP infection has been suggested to influence the
development of atherosclerotic changes in coronary arteries,
indicating a damaging effect of this bacterium or its products
(e.g., cytokines, endotoxins, cytotoxins, and other virulence
factors) on the coronary endothelium.
We found a positive association between HP infection
and CAD in addition to its severity whereas 76.3% of people
with MVD and 70% of patients with SVD were HP seropos-
itive while it was 50% in control group and 52.8% in patients
with nonspecific coronary artery involvement. Also, a pos-
itive correlation was found between HP seropositivity and
CAD (OR= 3.86, 95%CI = 1.48–10;𝑃 = 0.006).This is similar
to Rogha et al.’s study which found a positive association
betweenHP seropositivity and CAD in 112 patients candidate
for coronary angiography (OR 3.18, 95% CI = 1.08–9.40) [9].
Also, Vcev et al. showed this positive association [19]. The
results of this study showed a higher seroprevalence of HP
infection in patients with CAD compared to controls (78.8%
versus 58.3%). However, in this study HP seropositivity was
not associated with coronary artery disease risk factors like
smoking, total cholesterol, BMI, diabetes mellitus, hyperten-
sion, and socioeconomic status either in the whole study
population or in the patients and control subjects analyzed
separately [19].
In our study, HP seropositive patients had different risk
factors which were observed in other studies. Seropositivity
rates for HP were significantly higher in patients with coro-
nary artery disease than in controls (80.2% versus 54.5%; 𝑃 <
0.05) [20]. Even some researchers stated that this infection
will deteriorate the PTCA outcome. Kowalski found that the
mean lumen loss after PTCA with stent in HP-IgG positive
patients is higher compared to the HP-IgG negative patients
(𝑃 = 0.0196) [21]. In contrast, Rogha et al. did not confirm
the association between HP and CAD. They studied 105
subjects and found that HP infection and CagA Ab were not
significantly higher compared to the patients with severe and
mild CHD (𝑃 = 0.28 and 𝑃 = 0.68, resp.). Colonization of
CagA positive HP did not significantly associate with severity
of CHD (OR = 1.05, 95% CI = 0.33–3.39) [9].
In Jin et al.’s study 30.7% of the normal control group
and 40.6% of the CAD group were HP infection positive
but there was no statistical difference [15]. Wald et al. found
no association between HP seropositivity and ischemic heart
disease in their study [22]. Strachan and colleagues followed
the patients for 13 years and suggested that although HP does
not seem to cause CAD, it increases themortality rate in CAD
patients (OR = 1.52 (95% CI, 0.99 to 2.34)) [23].
It has been suggested that HP influences the IHD devel-
opment through different pathways like endothelial cells
colonization, lipid profile changes, increased coagulation and
platelet aggregation levels, induction of molecular mimicry
mechanisms, and the promotion of a low-grade systemic
inflammation [10].
On the other side, chronic HP infection is known to
increase the pH level of the gastric juice and to decrease
ascorbic acid levels, both of whichwill cause folate absorption
reduction. Low folate hampers themethionine synthase reac-
tion. This will increase blood hemocysteine concentration
which results in damage of endothelial cells [24]. Siddiqui
et al. evaluated the hemocysteine level in CAD patients with
HP infection and found no difference [25]. Also, large pop-
ulation-based studies suggested the relation between the CRP
levels and risk of coronary artery disease [24].The association
between HP infection and plasma levels of CRP, has been
investigated by Pienjzek et al. [26].
In our study, like Tamer et al. and Siddiqui et al.’s study, the
CRP level was higher in CAD patients. In Tamer et al.’s study,
CRP level was different among patients with and without
CAD but HP infection did not differ in both groups [20].
AlthoughCADpatients had higherCRP andESR levels in
our study, but assigning them intoHP+ve andHP−ve groups,
no difference was detected. Gastric infection with HP may
also induce the synthesis of acute phase reactants and activate
immune mechanisms due to cross-reacting antibodies to
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HP and heat shock protein (HSP 60/65) with endothelial-
derived HSP 60/65 [27, 28]. Mendall et al. found a strict
correlation between the increment in serum levels of some
proinflammatory cytokines (IL-1b, IL-8, and TNF-𝛼) and
cardiovascular risk factors [27].
Also some studies suggest the coagulability stimulation
caused by HP. Niemela¨ et al. and de Luis et al. have demon-
strated that HP infection causes thrombotic protein changes
[29, 30].The association betweenHP infection andfibrinogen
has been investigated by Pienjzek et al. [26]. One interesting
hypothesis is stimulated platelet aggregation by Helicobacter
pylori. Results showed that some HP strains are able to bind
to the von Willebrand factor to interact with glycoprotein
Ib and to induce platelet aggregation in humans and HP
may eventually affect IHD by eliciting thrombosis [31].
Also, Elizalde shows that circulating platelet aggregates and
activated platelets were also detected in HP infected patients
[32].
Thromboxane (TXB) is an index of platelet activation
which was found to be significantly higher in the HP+ and
CAD+ (𝑃 = 0.05), but not in the HP+ CAD− (𝑃 = 0.88)
when compared with HP− CAD− [33]. HP infection was
reported by Pellicano et al. to induce also platelet activation
and aggregation as well as an increase of plasma levels of
triglycerides and various proatherogenic factors including
hemocysteine [34]. Also, the seroprevalence of CagA positive
strains was significantly higher in patients with acute MI and
UA than controls (86.7, 91.7, and 58.3%, resp.) [17]. Kowalski
also reported that, in homogenous group of patients, those
with CAD had significantly higher HP IgG and CagA sero-
prevalence (69.79% versus 58.20%) as compared to non-CAD
controls (40.62% versus 35.89%) [21].
Although some studies do not confirm it, colonization
of CagA positive HP is not an independent risk factor for
severe coronary heart disease [9]. Some researchers evaluated
the effect of HP through metabolic changes (lipid profile).
Rahman et al. compared patients suffering from HP and
CAD with those suffering from HP without CAD and
analyses of lipid profiles showed that while triglycerides, total
cholesterol, and LDL had no significant changes, HDL was
significantly lower in both groups [33]. HP specific IgG was
positively correlatedwith triglyceride level [35]. Niemela¨ et al.
and de Luis et al. have shown that HP infection causes various
lipids and there is a good correlation between HP infection
and decreased HDL cholesterol [29, 30]. Also, Jia et al.
showed that HDL-c was significantly decreased in patients
with HP infection, indicating that HP infection may result
in decreased blood HDL-c levels, which then contributes to
the development of coronary atherosclerosis [36]. But in our
study, lipid profile was not different between seropositive
and seronegative patients and colonization of HP is an
independent risk factor for coronary heart disease.
5. Conclusion
According to our study, HP seropositive patients are at higher
risk for CAD and the number of their involved arteries is
greater. Given the high prevalence of HP infection and as
coronary artery disease is the major cause of mortality in this
population, this issue is of importance and in case of proving
this causal relationship, we can avoid mortality due to CAD.
Also, it seems that, in PTCA patients, HP treatment reduces
the stenosis.
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